Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight ...

The developer of an alternative surgical approach to glaucoma has raised $42 million to bolster the commercial launch of its ...

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

The years-long legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries ...

Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...